AQST Aquestive Therapeutics Inc
P/E
--
Forward P/E
--
Price/Sales
9.29
Beta
1.505
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Aquestive Posts a Blowout Quarter, but Can a Stamp-Sized Allergy Film Justify a Half-Billion-Dollar Bet?
Shares surged 12.8% to $4.66 after Aquestive Therapeutics delivered first-quarter results that caught Wall Street off guard — and not just on revenue. The...
🟢 AQST is trading 12.8% up today on a Q1 earnings beat and 66% revenue growth
AQST is trading at $4.66, up 12.8% today after reporting a 66% year-over-year revenue increase and a significant surge in license and royalty income. • Total...
Aquestive Therapeutics' first quarter revenue grew 66% as it reaffirms plans for a third quarter 2026 Anaphylm NDA resubmission.
Aquestive Therapeutics reported first quarter 2026 revenue of $14.4 million, a 66% increase from the prior year, and a net loss per share of $0.07. The company...
Aquestive Therapeutics Shares Climb Ahead of Q1 Results and Conference Call
Aquestive Therapeutics will report its Q1 2026 financial results and business highlights on May 13, 2026. The company scheduled a follow-up conference call for...